Value of Enhancer of Zeste Homolog 2 (EZH2) for Determining Prognosis in Colon Cancer

Value of Enhancer of Zeste Homolog 2 (EZH2) for Determining Prognosis in Colon Cancer


چاپ صفحه
پژوهان
صفحه نخست سامانه
چکیده مقاله
چکیده مقاله
نویسندگان
نویسندگان
دانلود مقاله
دانلود مقاله
دانشگاه علوم پزشکی تبریز
دانشگاه علوم پزشکی تبریز

نویسندگان: نسرین غلامی , زهره صناعت , رویا دولت خواه , علیرضا نیکانفر , علی اصفهانی , امین داننده مهر , اشرف فخرجو

کلمات کلیدی: Colorectal neoplasms, Disease-free, Immunolabeling technique, Survival

نشریه: 19694 , 3 , 14 , 2020

اطلاعات کلی مقاله
hide/show

نویسنده ثبت کننده مقاله زهره صناعت
مرحله جاری مقاله تایید نهایی
دانشکده/مرکز مربوطه مرکز تحقیقات هماتولوژی و انکولوژی
کد مقاله 71263
عنوان فارسی مقاله Value of Enhancer of Zeste Homolog 2 (EZH2) for Determining Prognosis in Colon Cancer
عنوان لاتین مقاله Value of Enhancer of Zeste Homolog 2 (EZH2) for Determining Prognosis in Colon Cancer
ناشر 8
آیا مقاله از طرح تحقیقاتی و یا منتورشیپ استخراج شده است؟ بلی
عنوان نشریه (خارج از لیست فوق) Journal of Clinical and Diagnostic Research
نوع مقاله Original Article
نحوه ایندکس شدن مقاله ایندکس شده سطح یک – ISI - Web of Science
آدرس لینک مقاله/ همایش در شبکه اینترنت

خلاصه مقاله
hide/show

Introduction: It has been reported that Enhancer of Zeste Homolog 2 (EZH2) enhancer is expressed in Colorectal Cancer (CRC), but there are only limited fndings of its overexpression with prognosis in CRC. Aim: To investigate the association between EZH2 expression and clinicopathologic variables and outcome in CRC. Materials and Methods: This retrospective study retrieved the archived histological samples for immunohistochemistry evaluation of EZH2 and PCR analysis of KRAS from patients with CRC who were followed-up between April 2009 and February 2019. Kaplan-Meier methods were used for Overall Survival (OS) and Disease-Free Survival (DFS). Cox proportional hazard model and time dependent Cox model were used to evaluating association of clinicopathologic factors with OS and DFS. Results: Hundred patients with CRC were included with mean age and range 57.39±13.52 years and 21-83 years. There were no signifcant association between OS (log-rank p-value=0.50) and DFS (log-rank p-value=0.74) with EZH2 expression. Third quartile of OS was 30.7 days and for DFS was 107.83 days. According to the result of multivariate cox regression after adjusting for confounding variables, there was no signifcant association between EZH2 and OS (HR =1.53, 95% CI=0.63-3.72, p=0.35). Also, a borderline association was observed between EZH2 and DFS (HR=11.08, 95% CI=1.02-119.72, p=0.05). There were no signifcant associations between the DFS, OS and other clinicopathologic parameters except for the stage, respectively (HR=3.51, 95% CI=1.71-7.20, p=0.001) (HR=3.55, 95% CI=1.71- 7.35, p=0.001). Conclusion: The expression of EZH2 in patients with CRC was not associated with clinical features, and does not appear to be associated with OS or DFS. EZH2 is an attractive target in cancer and much more research is clearly warranted.

نویسندگان
hide/show

نویسنده نفر چندم مقاله
نسرین غلامیاول
زهره صناعتدوم
رویا دولت خواهسوم
علیرضا نیکانفرچهارم
علی اصفهانیپنجم
امین داننده مهرششم
اشرف فخرجوهفتم

لینک دانلود مقاله
hide/show

نام فایل تاریخ درج فایل اندازه فایل دانلود
43176_CE[Ra1]_F(KM)_PF1_(AJ_OM)_PN(SL).pdf1398/12/06458596دانلود